Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2021-12-20 Regulatory Filings
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Update - Appendix 2A- Issue of shares and Options 16 pages 303.8KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes details about the entity, the type of securities being quoted, and references to previous announcements such as Appendix 3B. The document is regulatory in nature, related to securities issuance and quotation, and is not a financial report, earnings release, or management discussion. It is a formal regulatory filing required by the exchange to update or amend information about securities quotation. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), indicating it is not a mere announcement of a report but a detailed regulatory form submission.
2021-12-20 English
Notification of cessation of securities - LCT 4 pages 24.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the expiry of options and convertible securities for Living Cell Technologies Limited. It provides specific information about securities that have ceased, including ASX security codes, number of securities ceased, reasons for cessation, and updated issued capital figures. The document is a formal announcement about changes in the company's issued securities, specifically the cessation of certain options due to expiry. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an announcement related to capital changes, specifically cessation of securities. According to the filing definitions, announcements regarding changes in issued securities, including cessation or expiry of options, fall under 'Share Issue/Capital Change' (SHA). The document length is 3594 characters, which is relatively short but contains substantive information about capital changes, not just a notice of report publication. Therefore, the appropriate classification is SHA with high confidence.
2021-12-14 English
Application for quotation of securities - LCT 7 pages 30.2KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities on the ASX (Australian Securities Exchange) by Living Cell Technologies Limited. It details the types and numbers of securities to be quoted, issue dates, and distribution schedules. The document is a formal announcement related to the listing or quotation of securities rather than a financial report, earnings release, or management discussion. It does not contain financial statements or management commentary but focuses on the capital market transaction of securities quotation. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as new securities issuance and quotation.
2021-12-13 English
LCT to Issue Compensation Options 2 pages 147.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited regarding the issuance of compensation options related to a previous placement of shares and notes. It discusses the number of options to be issued, the terms of the options, and references compliance with Listing Rules. The document is relatively short (5464 characters) and is an announcement of a capital raising-related event, specifically the issuance of options as compensation. It does not contain financial statements, detailed financial analysis, or management discussion of results. It is not a full report but an update on financing activities related to share options issuance. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2021-12-12 English
Proposed issue of securities - LCT 6 pages 30.1KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Living Cell Technologies Limited. It details the type of securities, number of securities to be issued, issue date, conditions, fees, and purpose of the issue. The content focuses on the company's capital raising activities and changes to its capital structure. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a regulatory certification or legal proceeding. The document fits the description of a Capital/Financing Update, which covers updates on company fundraising and capital structure changes.
2021-12-12 English
Cleansing Notice 3 pages 167.8KB
Capital/Financing Update Classification · 95% confidence The document is a cleansing notice under Section 708AA(2)(f) of the Corporations Act 2001 (Cth) regarding the issue of options by way of placement to sophisticated and wholesale investors. It includes legal compliance statements about the issuance of options without disclosure under Part 6D.2 of the Corporations Act and confirms compliance with relevant provisions. The document does not contain financial statements, management discussion, or detailed financial results. It is an announcement related to capital raising activities, specifically the issuance of options and convertible notes. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 5867 characters, which is sufficient to be a full announcement rather than a brief notice or report publication announcement. Hence, the classification is CAP with high confidence.
2021-12-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.